Molecular Insights You Can Rely On

When faced with a difficult treatment decision, GPS Cancer® offers a precise and comprehensive molecular profile, providing oncologists with unprecedented insights into the molecular signature of each patient’s cancer to inform personalized treatment strategies. This unique profile:


Includes whole genome/exome sequencing of 20,000 genes and 3 billion base pairs

Incorporates whole transcriptome sequencing of over 200,000 RNA transcripts

Compares a patient’s tumor genome to their normal genome

Based on the tumor’s “molecular fingerprint”, GPS Cancer offers insight into therapies that may have potential benefit, including FDA approved therapies and active clinical trials, and therapies to which the cancer may be resistant. GPS Cancer is performed in CAP-accredited, CLIA-certified labs.

Research published in Oncotarget (April 2018)